Clinical trial
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
NCT00352079 · NCIC Clinical Trials Group, Other · Terminated
Key facts
| NCT number | NCT00352079 |
|---|---|
| Title | BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer |
| Official title | A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bladder Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | BCG vaccine, gefitinib, quality-of-life assessment |
| Enrollment | 41 |
| Start date | Jan 4, 2007 |
| Primary completion | Jan 6, 2012 |
| Completion | Jan 6, 2012 |
| First posted | Jul 14, 2006 |
| Last update posted | Aug 4, 2023 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: